^
Association details:
| Biomarker: | MYC overexpression |
|---|---|
| Cancer: | Mediastinal B Cell Lymphoma |
| Drug: | Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EXPLORATION OF TUMOR BIOPSY GENE SIGNATURES TO UNDERSTAND THE ROLE OF THE TUMOR MICROENVIRONMENT IN OUTCOMES TO LISOCABTAGENE MARALEUCEL (LISO-CEL)
Published date:
06/12/2020
Excerpt:
These analyses showed that high expression of cell cycle genes, MTORC1 signaling genes, EZH2 targets, and MYC targets were associated with lower immune infiltration following liso-cel treatment, suggesting that the lower response rate to liso-cel in pts with high expression of these genes may be due to inadequate immune infiltration following liso-cel treatment.
